Kimryn Rathmell, incoming director of the National Cancer Institute (Credit: Vanderbilt University)

November 17, 2023 12:57 PM ESTUpdated 01:50 PM

Biden taps Vanderbilt’s Kimryn Rathmell to succeed Bertagnolli as the NIH's cancer chief

Lia DeGroot

President Joe Biden selected Vanderbilt University’s medicine chair Kimryn Rathmell to serve as the next director of the National Cancer Institute, the White House …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biden taps Vanderbilt’s Kimryn Rathmell to succeed Bertagnolli as the NIH's cancer chief

Lia DeGroot

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Sofinnova outlines $550M fund after IPOs and M&A deals

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Biden taps Van­der­bilt’s Kim­ryn Rath­mell to suc­ceed Bertag­nol­li as the NI­H's can­cer chief

Lia DeGroot

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Biden taps Vanderbilt’s Kimryn Rathmell to succeed Bertagnolli as the NIH's cancer chief

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Sofinnova outlines $550M fund after IPOs and M&A deals

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.